Published in J Infect Dis on November 01, 2008
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.49
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis (2013) 2.47
Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol (2009) 2.43
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis (2013) 1.72
Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens. J Infect Dis (2011) 1.71
Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study. Lancet Haematol (2015) 1.60
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol (2009) 1.50
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun (2009) 1.39
World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. J Immunol (2009) 1.32
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis (2013) 1.30
A positive correlation between atypical memory B cells and Plasmodium falciparum transmission intensity in cross-sectional studies in Peru and Mali. PLoS One (2011) 1.21
Exposure-dependent control of malaria-induced inflammation in children. PLoS Pathog (2014) 1.16
Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood (2012) 1.13
Abnormal PfEMP1/knob display on Plasmodium falciparum-infected erythrocytes containing hemoglobin variants: fresh insights into malaria pathogenesis and protection. Microbes Infect (2012) 1.03
α-Thalassemia impairs the cytoadherence of Plasmodium falciparum-infected erythrocytes. PLoS One (2012) 0.99
Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites. J Infect Dis (2013) 0.99
High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics (2010) 0.97
Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria. Biochem Biophys Res Commun (2009) 0.95
Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife (2015) 0.94
Biochemical and immunological mechanisms by which sickle cell trait protects against malaria. Malar J (2013) 0.92
Cytoadherence in paediatric malaria: ABO blood group, CD36, and ICAM1 expression and severe Plasmodium falciparum infection. Br J Haematol (2012) 0.89
Mechanistic Studies of the Negative Epistatic Malaria-protective Interaction Between Sickle Cell Trait and α(+)thalassemia. EBioMedicine (2014) 0.88
Somatically Hypermutated Plasmodium-Specific IgM(+) Memory B Cells Are Rapid, Plastic, Early Responders upon Malaria Rechallenge. Immunity (2016) 0.88
Systems immunology of human malaria. Trends Parasitol (2012) 0.86
Haemoglobin variants and Plasmodium falciparum malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso. Malar J (2012) 0.86
Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine. Malar J (2011) 0.85
The V gene repertoires of classical and atypical memory B cells in malaria-susceptible West African children. J Immunol (2015) 0.84
Asymptomatic Multiclonal Plasmodium falciparum Infections Carried Through the Dry Season Predict Protection Against Subsequent Clinical Malaria. J Infect Dis (2015) 0.82
Relationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C. PLoS One (2013) 0.82
Novel Insights Into the Protective Role of Hemoglobin S and C Against Plasmodium falciparum Parasitemia. J Infect Dis (2015) 0.82
Effects of age, hemoglobin type and parasite strain on IgG recognition of Plasmodium falciparum-infected erythrocytes in Malian children. PLoS One (2013) 0.82
Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali. Malar J (2010) 0.82
Human genetics and malaria: relevance for the design of clinical trials. J Infect Dis (2008) 0.82
Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria. Malar J (2014) 0.82
The association between nutritional status and malaria in children from a rural community in the Amazonian region: a longitudinal study. PLoS Negl Trop Dis (2015) 0.81
Co-infection of long-term carriers of Plasmodium falciparum with Schistosoma haematobium enhances protection from febrile malaria: a prospective cohort study in Mali. PLoS Negl Trop Dis (2014) 0.81
Genetics of Sub-Saharan African Human Population: Implications for HIV/AIDS, Tuberculosis, and Malaria. Int J Evol Biol (2014) 0.80
Plasmodium falciparum Gametocyte-Specific Antibody Profiling Reveals Boosting through Natural Infection and Identifies Potential Markers of Gametocyte Exposure. Infect Immun (2015) 0.80
Sickle cell protection from malaria. Hematol Rep (2011) 0.78
Ex-vivo cytoadherence phenotypes of Plasmodium falciparum strains from Malian children with hemoglobins A, S, and C. PLoS One (2014) 0.78
Impact of acute malaria on pre-existing antibodies to viral and vaccine antigens in mice and humans. PLoS One (2015) 0.77
Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children. J Infect Dis (2015) 0.77
Hematological Indices in Malian Children Change Significantly During a Malaria Season and with Increasing Age: Implications for Malaria Epidemiological Studies. Am J Trop Med Hyg (2016) 0.75
The Regulation of Inherently Autoreactive VH4-34-Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West Africa. J Immunol (2016) 0.75
High Plasmodium falciparum longitudinal prevalence is associated with high multiclonality and reduced clinical malaria risk in a seasonal transmission area of Mali. PLoS One (2017) 0.75
Stage-dependent fate of Plasmodium falciparum-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria. Malar J (2016) 0.75
High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria. Front Immunol (2017) 0.75
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg (2000) 22.12
Common west African HLA antigens are associated with protection from severe malaria. Nature (1991) 9.43
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg (1990) 4.70
Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet (2005) 4.22
Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet (2002) 4.13
Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood (2000) 3.36
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med (2007) 2.94
Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature (2001) 2.87
Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health (2005) 2.57
Long-term asymptomatic carriage of Plasmodium falciparum protects from malaria attacks: a prospective study among Senegalese children. Clin Infect Dis (2008) 2.57
Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood (2005) 2.35
Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature (1978) 2.28
Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A (2008) 2.19
Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J (2006) 2.19
Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci U S A (1978) 2.14
Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet (1970) 2.11
An immune basis for malaria protection by the sickle cell trait. PLoS Med (2005) 2.08
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA (2007) 1.95
Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg (2002) 1.88
What does a single determination of malaria parasite density mean? A longitudinal survey in Mali. Trop Med Int Health (2000) 1.78
Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health (2004) 1.74
Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine (2007) 1.74
The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis (1999) 1.62
The etiology of severe anemia in a village and a periurban area in Mali. Blood (2004) 1.55
Plasmodium falciparum malaria vaccines in development. Expert Rev Vaccines (2008) 1.54
Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol (2004) 1.51
Glucose-6-phosphate-dehydrogenase deficiency, sickling, and malaria in African children in South Western Nigeria. Lancet (1967) 1.50
Detection of common deletional alpha-thalassemia-2 determinants by PCR. Am J Hematol (1994) 1.44
Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis (2008) 1.32
Frequencies of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency differ in highland and nearby lowland malaria-endemic areas of Kenya. Trans R Soc Trop Med Hyg (2004) 1.29
The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis (2005) 1.23
Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg (2004) 1.18
Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One (2007) 1.17
Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune population exposed to intense perennial transmission. Am J Trop Med Hyg (2000) 1.17
Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure. J Infect Dis (2003) 1.16
Human genetic factors related to susceptibility to mild malaria in Gabon. Genes Immun (2000) 1.13
Sickling in relation to morbidity from malaria and other diseases. Br Med J (1956) 1.00
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
The pathogenic basis of malaria. Nature (2002) 10.44
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis (2013) 6.06
A research agenda to underpin malaria eradication. PLoS Med (2011) 5.34
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med (2008) 4.95
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
The threat of artemisinin-resistant malaria. N Engl J Med (2011) 4.15
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun (2002) 4.02
Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Arch Intern Med (2011) 3.73
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun (2005) 3.72
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun (2002) 3.08
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med (2007) 2.94
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Plasmodium biology: genomic gleanings. Cell (2003) 2.89
The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity (2008) 2.88
Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine (2007) 2.88
Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol (2001) 2.86
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One (2008) 2.70
Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe (2008) 2.66
Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health (2005) 2.57
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol (2011) 2.54
The initiation of antigen-induced B cell antigen receptor signaling viewed in living cells by fluorescence resonance energy transfer. Nat Immunol (2005) 2.53
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J (2008) 2.49
Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.49
Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet (2010) 2.48
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis (2013) 2.47
Risk factors for malaria infection and anemia for pregnant women in the Sahel area of Bandiagara, Mali. Acta Trop (2003) 2.47
Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol (2009) 2.43
False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the hrp2 gene. Am J Trop Med Hyg (2012) 2.43
Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoites. Int J Parasitol (2004) 2.37
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.29
The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity (2009) 2.25
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med (2008) 2.24
Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites. J Infect Dis (2005) 2.24
Ethical data release in genome-wide association studies in developing countries. PLoS Med (2009) 2.23
Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol Biochem Parasitol (2006) 2.22
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine (2005) 2.21
A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med (2009) 2.21
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis (2004) 2.20
Space-time clustering of childhood malaria at the household level: a dynamic cohort in a Mali village. BMC Public Health (2006) 2.20
Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A (2008) 2.19
Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature (2005) 2.17
Valid consent for genomic epidemiology in developing countries. PLoS Med (2007) 2.14
A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine (2009) 2.12
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Parasite burden and severity of malaria in Tanzanian children. N Engl J Med (2014) 2.07
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
Advances and challenges in malaria vaccine development. J Clin Invest (2010) 2.03
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun (2006) 2.02
Successful field trial of attractive toxic sugar bait (ATSB) plant-spraying methods against malaria vectors in the Anopheles gambiae complex in Mali, West Africa. Malar J (2010) 2.01
Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling. Immunity (2010) 2.01
Community permission for medical research in developing countries. Clin Infect Dis (2005) 2.01
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg (2008) 1.95
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1.95
Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc Natl Acad Sci U S A (2011) 1.94